ABOUT ZOGENIX
Where Medicine Meets Technology
Zogenix is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Our first commercial product, SUMAVEL® DosePro™ (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix’s lead product candidate, ZX002, is a novel, oral, single-entity controlled-release formulation of hydrocodone currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy.
We believe we are differentiated by the unique characteristics of our marketed product and late stage product candidate, each of which addresses large market opportunities, as well as our established commercial infrastructure, our innovative technology and the depth of experience of our management team. The following represents the key attributes that help differentiate our company:
- Fully-integrated pharmaceutical company with established commercial infrastructure. We have a sophisticated and robust commercial infrastructure relative to many companies of similar size and stage of development in the pharmaceuticals industry. Our sales and marketing organization is comprised of approximately 100 professionals who are focused on the promotion of SUMAVEL DosePro.
- SUMAVEL DosePro, a differentiated new entrant in the migraine market that has demonstrated consistent monthly prescription growth since its launch.
Our first commercial product, SUMAVEL DosePro, was launched in January 2010. We believe it represents a valuable new migraine treatment option that will address the significant unmet medical needs of patients and physicians. - ZX002, a novel, controlled-release chronic pain therapy in Phase 3 clinical development. ZX002 has the potential to be the first approved single-entity, controlled-release formulation of hydrocodone, the most widely prescribed pharmaceutical product in the United States. ZX002 utilizes Elan Pharma International Limited’s proprietary Spheroidal Oral Drug Absorption System, or SODAS®, which serves to enhance the release profile of hydrocodone to provide consistent 12-hour pain relief relative to existing immediate-release formulations. In March 2010, we initiated our Phase 3 development program for ZX002.
- Validated, proprietary DosePro technology with broad range of potential applications. SUMAVEL DosePro, which utilizes our DosePro technology, is the first drug product approved by the FDA which allows for the needle-free, subcutaneous delivery of medication. We believe that DosePro has the potential to become a preferred delivery option for patients and physicians for many medications beyond sumatriptan, including small molecules and biologics, and are evaluating further internal development candidates and technology out-licensing opportunities.
- Experienced management team with unique commercial and development expertise, including CNS sales and marketing experience. Our management team has a proven clinical, regulatory, business development and commercialization track record at Zogenix and prior organizations, as well as significant expertise in CNS disorders and pain.
